| Investment Objective | |
| The investment objective of the scheme is to provide returns that before expenses, closely correspond to the total returns of securities as represented by Nifty Healthcare TRI, subject to tracking errors. However, the performance of scheme may differ from that of the underlying index due to tracking error.The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved. | |
| Fund Category: Exchange Traded Fund (ETF) | |
| Fund Snapshot | |
| Date of Allotment : Oct 20, 2021 | |
| Benchmark: Nifty Healthcare TRI | |
Fund Manager - Mr. Mehul Dama | Fund Manager - Ms. Priya Sridhar |
| Load Structure (as % of NAV) (Incl. for SIP) | |
| Entry Load: | NIL |
| Exit Load: | NIL |
| AUM as on July 31, 2026 (in ₹Crore) | |
| Monthly Average AUM | 81.02 |
| AUM as on last day | 82.10 |
| Base Expense Ratio (BER) | |
| Regular | 0.16% |
| BER excludes brokerage incurred towards execution of trades, transaction cost & statutory levies as applicable to investors. | |
| NAV as on July 31, 2026 | |
| NAV | 17.25 |
| Tracking Error as on July 31, 2026 | |
| Tracking Error Regular | 0.01% |
| Other Parameters | |
| Standard Deviation | 16.51% |
| Sharpe Ratio | 0.96 |
| Beta | 1.00 |
| Treynor Ratio | 0.16 |
| Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 5.41 % (FBIL Overnight MIBOR as on 31 July, 2026 for calculating Sharpe Ratio |
|
| Minimum Application Amount | |
| For Transactions Directly with the Fund: For Market Makers The Creation Unit size for the Scheme shall be 1,10,000 units and in multiples thereof. For Large Investors Min. application amount shall be Rs. 25 Crores and in multiples of Creation Unit Size. For Transactions on Stock Exchanges Units of ETF scheme can be traded (in lots of 1 Unit) during the trading hours on all trading days on NSE and BSE on which the Units are listed. |
|
| Market Maker | |
|
IRAGE Broking Services LLP Choice Equity Broking Private Ltd. East India Securities Ltd. Kanjalochana Finserv Private Ltd. Parvati Capital Market Private Ltd. |
|
| Sectoral Contribution(in %) |
![]() |
| Top 10 Portfolio Holdings |
![]() |
Sector/Issuer Name |
% of Net AUM |
| Equity & Equity Related | |
| Pharmaceuticals & Biotechnology | 79.81% |
| ● Sun Pharmaceutical Industries Ltd. | 18.31% |
| ● Divi''s Laboratories Ltd. | 8.89% |
| ● Cipla Ltd. | 7.20% |
| ● Torrent Pharmaceuticals Ltd. | 6.53% |
| ● Laurus Labs Ltd. | 6.14% |
| ● Dr. Reddy''s Laboratories Ltd. | 6.08% |
| ● Lupin Ltd. | 5.09% |
| Aurobindo Pharma Ltd. | 3.80% |
| Alkem Laboratories Ltd. | 2.92% |
| Glenmark Pharmaceuticals Ltd. | 2.92% |
| Biocon Ltd. | 2.64% |
| Zydus Lifesciences Ltd. | 2.45% |
| Mankind Pharma Ltd. | 2.43% |
| Ipca Laboratories Ltd. | 2.11% |
| Abbott India Ltd. | 1.26% |
| Piramal Pharma Ltd. | 1.06% |
| Healthcare Services | 20.02% |
| ● Apollo Hospitals Enterprise Ltd. | 8.00% |
| ● Max Healthcare Institute Ltd. | 7.10% |
| ● Fortis Healthcare Ltd. | 4.28% |
| Syngene International Ltd. | 0.64% |
| Net Cash and Cash Equivalent | 0.17% |
| Grand Total | 100.00% |
Miscellaneous includes securities with exposure of less than 0.01%
| Product Label | |
| Scheme Name | |
| Aditya Birla Sun Life Nifty Healthcare ETF An open ended exchange traded fund tracking Nifty Healthcare TRI |
|
| This product is suitable for investors who are seeking*: | |
|
|
Risk-o-meter ![]() |
Benchmark Risk-o-meter Nifty Healthcare TRI ![]() |
| *Investors should consult their financial advisors if in doubt whether the product is suitable for them. | |